… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the …
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre
… company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNAediting technology platform and its AX-0810 pipeline program …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform today announced that Company …